Though immunotherapy has to some extent improved the prognosis of patients with
advanced non‐small cell lung cancer (NSCLC), only a few patients benefit. Furthermore …

Background The advanced lung cancer inflammation index [ALI: body mass index× serum
albumin/neutrophil-to-lymphocyte ratio (NLR)] reflects systemic host inflammation, and is …

Immunotherapy resistance in non–small cell lung cancer (NSCLC) may be mediated by an
immunosuppressive microenvironment, which can be shaped by the mutational landscape …

Exosomal PD-L1 has been increasingly considered a noninvasive and accurate predictive
marker for immunotherapy treatment response. However, the clinical monitoring of exosomal …

Emerging evidence has revealed that the removal of N-linked glycosylation could enhance
PD-L1 detection. However, whether PD-L1 antibodies against different epitopes of PD-L1 …

Background: The gut microbiome plays a critical role in modulating the therapeutic effect of
immune checkpoint inhibitors (ICIs). Proton pump inhibitors (PPIs) are commonly used in …

Formins are evolutionarily conserved genes and profoundly affect cancer progression. This
study aims to explore the expressions, prognostic values, and immunological correlations of …

The gastrointestinal microbiome has been shown to play a key role in determining the
responses to cancer immunotherapy, including immune checkpoint inhibitor (ICI) therapy …

Abstract Introduction PD-L1 (Programmed Cell Death Ligand 1) is currently the only
recognised marker of response to immunotherapy with anti-PD-1 or anti-PD-L1 antibodies in …

Non‐small cell lung cancer (NSCLC) is one of the most common types of cancer in the world
and has a 5‐year survival rate of~ 20%. Immunotherapies have shown promising results …